Clinical Framework for Managing Hypogonadism and Low Testosterone in Men

Low testosterone is one of the most over-diagnosed and under-diagnosed conditions in men’s health. Over-diagnosed because the symptoms (tiredness, low mood, reduced libido, loss of motivation) overlap with many other conditions: depression, chronic stress, undiagnosed thyroid disease (checked with a thyroid blood test), obstructive sleep apnoea, even iron deficiency. Under-diagnosed because most men never get tested properly, and many who do are tested at the wrong time of day with the wrong markers.

This article is the clinical reference document our team uses when we work through a suspected low testosterone case at 134 Harley Street. It is structured for clinicians, written in clinical language, and aligned to the British Society for Sexual Medicine and European Association of Urology guidelines. If you are investigating your own symptoms and want a friendlier overview of what low testosterone feels like, read our patient guide to low testosterone symptoms in men, or book a testosterone blood test directly. If you want the full evidence base and the protocol our doctors actually follow, read on.

Executive Summary

This paper establishes an evidence-based clinical framework for the identification, diagnosis, and management of male hypogonadism. It addresses the physiological complexities of androgen production, the systemic nature of symptom presentation, modifiable lifestyle drivers, and regulatory safeguards. Designed for implementation within premier clinical settings, this framework prioritises diagnostic precision and patient safety through rigorous adherence to established endocrine guidelines.

Core Medical Premises and Physiological Accuracy

Free Testosterone

A persistent flaw in public health literature is focusing entirely on Total Testosterone. Most circulating testosterone is bound to proteins, chiefly Sex Hormone-Binding Globulin (SHBG) and albumin, and conditions that raise or lower SHBG can move the total result away from the fraction available to tissues. A patient can therefore present with a seemingly normal total score and still have symptoms if raised SHBG leaves less free, bioavailable hormone. The Endocrine Society recommends obtaining a free testosterone measurement when total testosterone is near the lower limit of normal or when a condition alters SHBG [13], and BSSM advises checking SHBG where total testosterone is borderline, particularly in obese and older men [12]. The binding models that underlie free testosterone calculations are themselves debated [1], which is one reason free testosterone should be read alongside the clinical picture rather than alone.

Free testosterone measurement is most informative when total testosterone falls in a borderline range (BSSM suggests 8 to 12 nmol/L) or when clinical symptoms persist despite apparently normal total levels [12]. Calculated free testosterone, derived from total testosterone, SHBG and albumin, is preferred to direct analogue immunoassay methods, which EAU and BSSM state are unable to estimate free testosterone accurately and should be avoided [4,12]. Equilibrium dialysis is the most accurate reference method [4].

The Diurnal Rhythm

Endocrine evaluation requires strict scheduling due to natural hormonal fluctuations. EAU recommends measuring total testosterone in the morning, between 07:00 and 11:00, and in the fasting state, noting that testosterone follows a circadian rhythm and is influenced by food intake [3,4]. BSSM also specifies 7 am to 11 am; it notes that evidence for fasting samples is limited, but that a 75 g glucose load lowered testosterone by about 25% and that fasting is appropriate for a first test [12]. A late-day or post-prandial sample can therefore produce a falsely low result.

The Oestradiol Balance

Comprehensive androgen profiling should consider downstream metabolic pathways, specifically those involving Oestradiol and Dihydrotestosterone (DHT). Testosterone is converted to oestradiol by the aromatase enzyme, and EAU describes the hypothesis that excess adipose tissue increases aromatase activity and oestrogen levels, impairing the hypothalamic-pituitary-gonadal (HPG) axis [4]. Oestradiol is not just a by-product. In a randomised study of healthy men aged 20 to 50 whose own testosterone and oestradiol were suppressed, testosterone deficiency accounted for the loss of lean mass, muscle size and strength, oestrogen deficiency primarily accounted for the increase in body fat, and both contributed to the decline in sexual function [5]. Oestradiol should therefore be interpreted alongside testosterone, particularly in men with a raised BMI or visceral adiposity. DHT, produced via 5-alpha reductase activity, is relevant to prostate health and virilisation and should be considered where clinical presentation warrants.

Nuanced Symptom Profiling and Differential Diagnosis

Overlapping Presentation

The clinical presentation of low testosterone is rarely single-faceted. Many symptoms lack specificity: BSSM lists fatigue, sleep disturbance, loss of physical strength, reduced energy and motivation, and depressed mood as less-specific symptoms, and EAU states that symptoms of hypogonadism are non-specific and need to be taken in context with the clinical and biochemical state [4,12]. These can closely mimic clinical depression, chronic stress or hypothyroidism. Both guidelines base the diagnosis on consistent symptoms together with consistently low morning testosterone, so confirmation of a clinical suspicion by hormonal testing is required rather than optional [4,6,12].

Specific Indicators

Sexual symptoms are the most specific: EAU grades this as level 1a evidence, and BSSM describes low sexual desire, reduced morning and night-time erections and erectile dysfunction as particularly suggestive of testosterone deficiency when they occur together [4,12]. Examination may show reduced body hair, decreased testicular size or gynaecomastia, although BSSM notes these signs are not always present [12]. These features carry more diagnostic weight than generalised fatigue or mood disturbance.

The Threshold Nuance

Objective laboratory values must be interpreted alongside subjective clinical presentations. There is no universal threshold at which symptoms reliably appear: a cohort study of 434 men reviewed by BSSM found that loss of erections, diabetes, depression, obesity and reduced vigour appeared at different testosterone levels, from about 8 nmol/L to 15 nmol/L, with no uniform pattern [12]. EAU likewise notes that no validated free testosterone thresholds are available from clinical studies [4]. A combined biochemical and clinical approach is required, and neither criterion should be applied in isolation.

High-Risk Demographics and Modifiable Factors

The Adipose Tissue Loop

Low testosterone is common in men with obesity, and EAU links it with greater visceral adiposity and fat mass [4]. Corona and colleagues describe a bidirectional relationship: having hypogonadism increases the risk of visceral obesity, and obesity induces incident hypogonadism. They state that the mechanism is not completely understood, with diet-induced hypothalamic inflammation and reduced GnRH release a plausible route [7]. The 2016 American Association of Clinical Endocrinologists obesity guideline, as summarised by BSSM, recommends that men with a waist circumference over 102 cm (40 inches) or a BMI over 30 kg/m2 are assessed for testosterone deficiency by history, examination and a testosterone measurement [12].

Sleep Architecture

Testosterone secretion follows a sleep-related rhythm. In 10 men studied on an ultrashort sleep-wake schedule, the nocturnal rise in testosterone was linked to the first episode of REM sleep, and fragmented sleep delayed the rise and attenuated it in men who did not reach REM sleep, although mean levels were similar to men who slept continuously [14]. In a small study of 10 men with obstructive sleep apnoea and 5 controls, overnight LH and testosterone secretion were significantly lower in the men with sleep apnoea, and the amounts secreted correlated with the severity of respiratory disturbance; four of the 10 had hypogonadal morning testosterone levels [9]. These are small studies, so they support considering sleep apnoea in a symptomatic man rather than treating it as a proven cause. The Endocrine Society recommends against starting testosterone therapy in men with untreated severe obstructive sleep apnoea [13].

Medication-Induced Suppression

Clinicians must conduct a thorough pharmaceutical review during evaluation. BSSM lists oral glucocorticoids, opioids, anticonvulsants and antipsychotics among medicines that may suppress testosterone, and reports hypogonadism in 25% to 80% of men on long-term prescribed opiates, depending on the drug and dose [12]. EAU also lists opiates and glucocorticoids among drug-induced causes of secondary hypogonadism [4]. A 2025 Norwegian cohort of 295 men receiving opioid agonist therapy found low free testosterone in 80% at baseline, but no association between free testosterone and fatigue or psychological distress, and the authors urge caution because of limited power and confounding [10]. A low result in a man taking an opioid should therefore be confirmed and interpreted with the symptoms rather than assumed to explain them.

Reference Ranges and Diagnostic Protocols

Reference intervals support clinical decision-making but are not a substitute for clinical judgement. Assay method and laboratory-specific calibration should always be considered when interpreting individual results, and BSSM notes that reference ranges for testosterone are not designed to replace evidence-based guidelines [12]. The International Society for the Study of the Aging Male (ISSAM) publishes separate international recommendations on the diagnosis, treatment and monitoring of testosterone deficiency [8].

Marker	Reference value	Clinical Note
Total Testosterone	Lower limit in healthy nonobese young men: about 12.1 nmol/L (348 ng/dL)	Framingham Heart Study, men aged 19 to 40, measured by LC-MS/MS: 2.5th percentile [11]. EAU 2024 gives 12 nmol/L as a threshold for starting therapy in symptomatic men [4]. BSSM says a total testosterone below 12 nmol/L (on two separate 8 to 11 am samples) usually requires treatment in symptomatic men, and 8 to 14 nmol/L may justify a trial of at least 6 months [12]. Diagnosis must not rely on a single value.
Free Testosterone (equilibrium dialysis, all adult men)	229 to 1072 pmol/L	Healthy nonobese men by a standardised equilibrium dialysis method. Men aged 19 to 39 have a narrower reference of 415 to 1274 pmol/L [2]. BSSM treats a calculated free testosterone below 225 pmol/L as supportive evidence for treatment in the presence of symptoms [12]. Assay method significantly affects reported values.
LH	Laboratory-specific	Required to distinguish primary from secondary hypogonadism [4,12]. Elevated LH with low testosterone points to primary testicular failure. Suppressed or inappropriately normal LH points to HPG axis dysfunction.
Oestradiol (E2)	Laboratory-specific	Assess in the context of testosterone, particularly in patients with elevated BMI or visceral adiposity. Use the reference range printed on your own report.

At WMG Health, our Testosterone Panel and the broader Hormone Specialist Panel are both drawn between 8am and 10am. Fasting beforehand is preferred but not essential (8 to 12 hours for the Testosterone Panel, 9 to 12 hours for the Hormone Specialist Panel), and results are clinician-reviewed before release.

The Two-Sample Rule

EAU recommends repeating total testosterone on at least two separate occasions when it is below 12 nmol/L and before starting treatment [4]. BSSM recommends measurement between 7 am and 11 am on at least two occasions, preferably 4 weeks apart and, if possible, not during an acute illness [12]. This safeguard helps avoid starting long-term therapy on the basis of a transient low result, for example during an acute illness, before a single draw.

Clinical Note: LH Requirement

LH measurement is not optional. EAU recommends analysing LH and FSH to differentiate between the types of hypogonadism, and BSSM recommends LH to separate primary from secondary testosterone deficiency, with LH and FSH measured when total testosterone is below 12 nmol/L [4,12]. Primary hypogonadism (testicular failure) and secondary hypogonadism (HPG axis dysfunction) have distinct aetiologies and different management pathways. A diagnosis built solely on testosterone values without gonadotropin data is clinically incomplete.

Safety, Governance, and Treatment Cautions

Lifestyle Intervention

Weight loss and lifestyle change are an important part of management, and EAU states they should be the first approach in overweight and obese men with hypogonadism. A meta-analysis cited by EAU found that a low-calorie diet can reverse obesity-associated secondary hypogonadism, although the rise in testosterone is small (1 to 2 nmol/L) and most lost weight is regained over time [4]. A meta-analysis of intervention studies likewise concluded that treating obesity is a very efficient treatment for obesity-induced hypogonadism [7]. BSSM takes a more cautious position: because symptoms may not improve when biochemistry does, it does not support lifestyle intervention alone as first-line therapy in men with symptomatic deficiency and endorses lifestyle modification in conjunction with testosterone therapy [12]. Structured exercise, sleep and weight management should therefore be addressed in every case, and the choice between lifestyle measures alone and treatment is an individual clinical decision.

Testosterone Replacement Therapy: Side Effects and Monitoring

When intervention is clinically indicated, unmonitored therapy carries a significant risk. Management requires adherence to a structured monitoring plan across the following parameters:

• Polycythaemia. Testosterone therapy can cause increased red blood cell mass and elevated haematocrit. The Endocrine Society’s standard monitoring plan includes measuring haematocrit during the first year after starting treatment [13], and EAU advises that a haematocrit above 54% should lead to withdrawal, dose reduction, a change of formulation or venesection, with lower baseline values (48 to 50%) evaluated carefully before starting [4]. Regular Full Blood Count monitoring is therefore a core safety requirement.
• Fertility and structural changes. Exogenous testosterone suppresses gonadotropin and endogenous testosterone secretion and impairs spermatogenesis, which EAU describes as temporary inhibition of the pituitary, and treatment is contraindicated in men who wish to father children [4,13]. Patients should receive pre-treatment counselling on this, with the risks and benefits discussed before treatment starts [13].
• Prostate health. The Endocrine Society’s monitoring plan includes evaluating prostate cancer risk during the first year [13], and BSSM states that careful assessment of the prostate before starting, and regular monitoring for prostate disease afterwards, remain essential [12]. Untreated prostate or breast cancer is an absolute contraindication to testosterone therapy. Severe lower urinary tract symptoms (LUTS, IPSS score above 19) represent a relative contraindication and warrant specialist review before starting [4].
• Prolactin and pituitary disease. Hyperprolactinaemia is a treatable cause of secondary hypogonadism. EAU recommends measuring prolactin when low sexual desire or other suggestive symptoms occur with secondary hypogonadism, and pituitary MRI in secondary hypogonadism with raised prolactin, symptoms of a pituitary mass or other anterior pituitary hormone deficiency [4]. BSSM advises measuring prolactin when both LH and FSH are low [12]. Pituitary pathology should be excluded in these men before treatment is considered.

Clinical Governance and Service Pathway

To manage patient expectations and maintain transparent clinical boundaries, the operational structure of the medical pathway must be explicitly stated. The initial assessment service operates as a structured rapid diagnostic pathway: confirming or excluding biochemical hypogonadism, stratifying risk, and recommending lifestyle or referral pathways where appropriate.

Following stabilisation of diagnostic data and confirmation of pathology, onward referral pathways are established to transfer care to specialist endocrinologists within Westminster Medical Group for long-term management. Patients are informed of this tiered structure at the point of initial consultation, with written documentation of the transition criteria and expected timelines.

All documentation, CAPA reporting, and treatment monitoring adhere to the clinical governance standards of the Care Quality Commission and relevant BSSM and EAU guideline frameworks.

References

1. Goldman AL, Bhasin S, Wu FCW, Krishna M, Matsumoto AM, Jasuja R. A reappraisal of testosterone’s binding in circulation: physiological and clinical implications. Endocr Rev. 2017;38(4):302-324. doi:10.1210/er.2017-00025
2. Jasuja R, Pencina KM, Spencer DJ, Peng L, Privat F, Dhillo W, Jayasena C, Hayes F, Yeap BB, Matsumoto AM, Bhasin S. Reference intervals for free testosterone in adult men measured using a standardized equilibrium dialysis procedure. Andrology. 2023;11(1):125-133. doi:10.1111/andr.13310
3. European Association of Urology. Guidelines on Sexual and Reproductive Health. EAU Guidelines Office, Arnhem, Netherlands. Limited update April 2024. Available at: uroweb.org/guidelines/sexual-and-reproductive-health
4. Salonia A, Bettocchi C, Capogrosso P, et al. EAU Guidelines on Sexual and Reproductive Health, section 3: Male Hypogonadism. European Association of Urology, limited update April 2024. Full guideline PDF
5. Finkelstein JS, Lee H, Burnett-Bowie SM, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-1022. doi:10.1056/NEJMoa1206168
6. Khera M, Torres LO, Grober ED, Morgentaler A, Miner M, Jones TH, Mills JN, Salonia A. Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). Sex Med Rev. 2025;13(4):548-573. doi:10.1093/sxmrev/qeaf036
7. Corona G, Vignozzi L, Sforza A, Mannucci E, Maggi M. Obesity and late-onset hypogonadism. Mol Cell Endocrinol. 2015;418(Pt 2):120-133. doi:10.1016/j.mce.2015.06.031
8. Lunenfeld B, Mskhalaya G, Zitzmann M, Corona G, Arver S, Kalinchenko S, Tishova Y, Morgentaler A. Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men. Aging Male. 2021;24(1):119-138. doi:10.1080/13685538.2021.1962840
9. Luboshitzky R, Aviv A, Hefetz A, Herer P, Shen-Orr Z, Lavie L, Lavie P. Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J Clin Endocrinol Metab. 2002;87(7):3394-3398. doi:10.1210/jcem.87.7.8663
10. Vold JH, Vogt EC, Heldal AT, Chalabianloo F, Druckrey-Fiskaaen KT, Loberg EM, Methlie P, Johansson KA, Fadnes LT. Low testosterone among males in opioid agonist therapy and its association with fatigue and psychological distress. J Endocr Soc. 2025;9(9):bvaf114. doi:10.1210/jendso/bvaf114
11. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96(8):2430-2439. doi:10.1210/jc.2010-3012
12. Hackett G, Kirby M, Rees RW, Jones TH, Muneer A, Livingston M, Ossei-Gerning N, David J, Foster J, Kalra PA, Ramachandran S. The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice. World J Mens Health. 2023;41(3):508-537. doi:10.5534/wjmh.221027
13. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229
14. Luboshitzky R, Zabari Z, Shen-Orr Z, Herer P, Lavie P. Disruption of the nocturnal testosterone rhythm by sleep fragmentation in normal men. J Clin Endocrinol Metab. 2001;86(3):1134-1139. doi:10.1210/jcem.86.3.7296

---

This article is for general clinical information and does not constitute personalised medical advice. If you have concerns about your symptoms, book an appointment or speak to your GP.